🎤 We’re delighted that ICR's Professor Paul Workman is speaking on a panel today at The Galien Foundation Forum at the @sciencemuseum.org.uk where this year’s focus is Future Health Disrupted: From Discovery to Delivery.
Professor Workman will share his insights on the incredible progress in discovering new precision cancer medicines, and how disruptive technologies are accelerating this progress. This includes advances in PROTACs, molecular glues and the critical role of biomarkers in patient selection.
UK research shows cancer trials may be unintentionally excluding some of the patients who could benefit most. From explicit criteria like HIV status to less visible barriers like language, access isn’t always equal.
Rethinking trial design is key to making research more inclusive and effective.
He will also highlight the growing importance of computational approaches and machine learning/AI in areas such as target identification, druggability analysis (e.g. using canSAR), and hit discovery.
More from here us ⬇️
Making clinical trials more inclusive isn’t just about fairness; it’s about better science. By widening access and considering underserved groups from the outset, researchers can build stronger evidence and help ensure that new cancer treatments work for everyone who needs them.
Only about 10% of cancer patients take part in clinical trials, and this new study explains why.
Eligibility criteria meant to protect participants can also
limit inclusion, reducing the number of people who benefit from innovation and producing evidence that may not reflect real-world populations
New findings from the OrigAMI-4, a study led by Professor Kevin Harrington in advanced head and neck cancer are presented today at #ASCO2026 ⤵️
www.asco.org/abstracts-pr...
🎙️ICR's Professor Kevin Harrington spoke to Naga Munchetty and Chris Smith on @bbc5live.bsky.social
He spoke about how the early discoveries were made that viruses could infect tumours, and how this has led to modern, genetically engineered viruses to treat cancer - called oncolytic virotherapy.
